Alimera Sciences announces expansion of agreement with Horus Pharma

Alimera Sciences announces that it has further expanded its relationship with Horus Pharma, one of the Company’s current distributors of ILUVIEN in Europe. Alimera and Horus have agreed to expand their relationship beyond France, Belgium, Luxembourg and the Netherlands to increase the commercialization efforts for ILUVIEN for both diabetic macular edema and non-infectious uveitis affecting the posterior segment of the eye in the Nordic countries of Denmark, Finland, Norway and Sweden. "We continue to see great results from Horus selling ILUVIEN and believe they will leverage their marketing and medical expertise to bring ILUVIEN to more patients in these markets," said Rick Eiswirth, President and Chief Executive Officer of Alimera. "Their belief in ILUVIEN and its ability to treat inflammation consistently and continuously, beginning early in the disease, coupled with their developing commercial infrastructure in these markets, makes Horus the logical partner for the Nordics."